Cargando…

Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy

OBJECTIVE: To study the macular sensitivity after half-dose verteporfin photodynamic therapy in patients with resolved central serous chorioretinopathy using the automated static perimeter. METHODS: Prospective consecutive case study of 24 patients with resolved central serous chorioretinopathy was...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanguansak, Thuss, Pitujaturont, Prapapan, Yospaiboon, Yosanan, Sinawat, Suthasinee, Ratanapakorn, Tanapat, Bhoomibunchoo, Chavakij
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671812/
https://www.ncbi.nlm.nih.gov/pubmed/26664040
http://dx.doi.org/10.2147/OPTH.S95748
_version_ 1782404459708547072
author Sanguansak, Thuss
Pitujaturont, Prapapan
Yospaiboon, Yosanan
Sinawat, Suthasinee
Ratanapakorn, Tanapat
Bhoomibunchoo, Chavakij
author_facet Sanguansak, Thuss
Pitujaturont, Prapapan
Yospaiboon, Yosanan
Sinawat, Suthasinee
Ratanapakorn, Tanapat
Bhoomibunchoo, Chavakij
author_sort Sanguansak, Thuss
collection PubMed
description OBJECTIVE: To study the macular sensitivity after half-dose verteporfin photodynamic therapy in patients with resolved central serous chorioretinopathy using the automated static perimeter. METHODS: Prospective consecutive case study of 24 patients with resolved central serous chorioretinopathy was performed. The macular sensitivity was measured using a conventional automated static perimeter with the Swedish interactive threshold algorithm 10-2 and foveal threshold. Best corrected visual acuity, intraocular pressure, fundus examination, macular thickness, and volume were also examined. The mean macular sensitivities of the affected eyes and their normal fellow eyes were calculated and compared. P<0.05 was considered statistically significant. RESULTS: The mean macular sensitivities of the affected eyes were lower than the normal fellow eyes with a statistically significant difference in all areas of the study (P<0.05). Best corrected visual acuity improved significantly from pretreatment (0.26±0.3 logMAR) to posttreatment (0.075±0.15 logMAR, P<0.05). Macular thicknesses in affected eyes were 230.66±67.34 μm and in the normal eyes were 238.33±92.26 μm (P=0.68). Macular volumes in affected eyes were 8.77±0.49 and in the normal eyes were 8.70±0.50 (P=0.60). These findings were not statistically significant. CONCLUSION: Eyes with resolved central serous chorioretinopathy after half-dose verteporfin photodynamic therapy had lower macular sensitivity than normal fellow eyes. These findings agreed well with the previous microperimetric studies. The conventional automated static perimeter can also be used when a microperimeter is not available.
format Online
Article
Text
id pubmed-4671812
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46718122015-12-09 Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy Sanguansak, Thuss Pitujaturont, Prapapan Yospaiboon, Yosanan Sinawat, Suthasinee Ratanapakorn, Tanapat Bhoomibunchoo, Chavakij Clin Ophthalmol Original Research OBJECTIVE: To study the macular sensitivity after half-dose verteporfin photodynamic therapy in patients with resolved central serous chorioretinopathy using the automated static perimeter. METHODS: Prospective consecutive case study of 24 patients with resolved central serous chorioretinopathy was performed. The macular sensitivity was measured using a conventional automated static perimeter with the Swedish interactive threshold algorithm 10-2 and foveal threshold. Best corrected visual acuity, intraocular pressure, fundus examination, macular thickness, and volume were also examined. The mean macular sensitivities of the affected eyes and their normal fellow eyes were calculated and compared. P<0.05 was considered statistically significant. RESULTS: The mean macular sensitivities of the affected eyes were lower than the normal fellow eyes with a statistically significant difference in all areas of the study (P<0.05). Best corrected visual acuity improved significantly from pretreatment (0.26±0.3 logMAR) to posttreatment (0.075±0.15 logMAR, P<0.05). Macular thicknesses in affected eyes were 230.66±67.34 μm and in the normal eyes were 238.33±92.26 μm (P=0.68). Macular volumes in affected eyes were 8.77±0.49 and in the normal eyes were 8.70±0.50 (P=0.60). These findings were not statistically significant. CONCLUSION: Eyes with resolved central serous chorioretinopathy after half-dose verteporfin photodynamic therapy had lower macular sensitivity than normal fellow eyes. These findings agreed well with the previous microperimetric studies. The conventional automated static perimeter can also be used when a microperimeter is not available. Dove Medical Press 2015-12-01 /pmc/articles/PMC4671812/ /pubmed/26664040 http://dx.doi.org/10.2147/OPTH.S95748 Text en © 2015 Sanguansak et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Sanguansak, Thuss
Pitujaturont, Prapapan
Yospaiboon, Yosanan
Sinawat, Suthasinee
Ratanapakorn, Tanapat
Bhoomibunchoo, Chavakij
Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
title Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
title_full Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
title_fullStr Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
title_full_unstemmed Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
title_short Macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
title_sort macular sensitivity after half-dose verteporfin photodynamic therapy in central serous chorioretinopathy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671812/
https://www.ncbi.nlm.nih.gov/pubmed/26664040
http://dx.doi.org/10.2147/OPTH.S95748
work_keys_str_mv AT sanguansakthuss macularsensitivityafterhalfdoseverteporfinphotodynamictherapyincentralserouschorioretinopathy
AT pitujaturontprapapan macularsensitivityafterhalfdoseverteporfinphotodynamictherapyincentralserouschorioretinopathy
AT yospaiboonyosanan macularsensitivityafterhalfdoseverteporfinphotodynamictherapyincentralserouschorioretinopathy
AT sinawatsuthasinee macularsensitivityafterhalfdoseverteporfinphotodynamictherapyincentralserouschorioretinopathy
AT ratanapakorntanapat macularsensitivityafterhalfdoseverteporfinphotodynamictherapyincentralserouschorioretinopathy
AT bhoomibunchoochavakij macularsensitivityafterhalfdoseverteporfinphotodynamictherapyincentralserouschorioretinopathy